PFS
ALXN

Prospera Financial Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Prospera Financial Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,989
Closed -$366K – 865
2021
Q2 		$366K Sell
1,989
-166
-8% -$28.5K 0.02% 612
2021
Q1 		$330K Sell
2,155
-145
-6% -$22.4K 0.02% 593
2020
Q4 		$360K Buy
2,300
+1,851
+412% +$238K 0.02% 489
2020
Q3 		$51K Sell
449
-1,550
-78% -$167K 0.02% 616
2020
Q2 		$224K Buy
+1,999
New +$212K 0.02% 515

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Prospera Financial Services's ALXN Position: Q3 2021 in Review

Prospera Financial Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,989 shares — an estimated $366K sold.

Prospera Financial Services first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $366K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Prospera Financial Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Prospera Financial Services sold 1,989 Alexion Pharmaceuticals shares in Q3 2021, an estimated $366K.
  • Prospera Financial Services first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Prospera Financial Services's Alexion Pharmaceuticals position peaked at $366K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Prospera Financial Services's 13F filing for Q3 2021, filed 12 Nov 2021.